**Background**
Matrix metalloproteinase-9 (MMP-9), also known as gelatinase B, is a zinc-dependent endopeptidase that plays a critical role in the degradation of extracellular matrix components. Overexpression and overactivation of MMP-9 are associated with various inflammatory conditions and tissue remodeling processes. In the context of the ocular surface, elevated levels of MMP-9 are frequently observed in patients with dry eye disease, where it contributes to corneal epithelial damage and chronic inflammation. Consequently, the development of highly selective MMP-9 inhibitors has become a significant research focus for treating ocular surface disorders. In this context, we will introduce a selective inhibitor of human MMP9 – MMP-9-IN-13.
**Definition**
MMP-9-IN-13 is a selective inhibitor of human MMP9 with an IC50 value of 0.02 nM.
**In Vitro Studies**
Regarding the MMP-9-IN-13 description, this compound is a derivative of 5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione. The MMP-9-IN-13 formula is C26H27F3N4O6, with a molecular weight of 548.51. In terms of MMP-9-IN-13 biological activity, the compound demonstrates potent and selective inhibition of the MMP-9 enzyme, making it a valuable tool for investigating the molecular mechanisms of dry eye disease. By targeting the active site of MMP-9, it prevents the proteolytic degradation of the ocular surface matrix. In conclusion, MMP-9-IN-13 is a highly potent and selective MMP-9 inhibitor suitable for research on the treatment of dry eye disease and ocular surface inflammation.
Keywords
MMP-9-IN-13, 3085676-77-0, MMP, Matrix metalloproteinases, MMP9, ocular surface, Inhibitor, inhibitor, inhibit
References